Education
About Us
Working with TipRanks
Follow Us
Vaxcyte, Inc. (PCVX)
NASDAQ:PCVX
PCVX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$28.46 - $121.06
Previous CloseN/A
Volume105.48K
Average Volume (3M)2.37M
Market Cap
$4.19B
Enterprise Value$8.55B
Total Cash (Recent Filing)-$66.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.52
Next Earnings
May 12, 2025EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.88
Shares Outstanding128,761,630
10 Day Avg. Volume4,563,842
30 Day Avg. Volume2,373,013
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-21.60
P/FCF Ratio0.00
Enterprise Value/Market Cap2.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-18.62
Forecast
1Y Price Target
$124.13Price Target Upside311.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Innovation And ExpansionThe newly announced VAX-XL was highlighted, indicating ongoing innovation and expansion in Vaxcyte's pipeline.
Market PositioningAnalysts reiterate Buy on PCVX’s underappreciated competitive positioning in the huge $8b+ PCV category.
Optimism For Future TrialsManagement plans to optimize protein carrier allocation for the missed serotypes, which could drive better results in Phase 3.
Bears Say
Clinical Trial ResultsThe VAX-24 infant study missed post-dose 3 primary serotype conversion rate non-inferiority criteria on 4 of 24 serotypes relative to Prevnar 20.
Investor ExpectationsThe topline data from the Ph2 trial evaluating VAX-24 in infants was below the relatively high Street expectations.
Management ConfidenceThere is less confidence that both VAX-24 & VAX-31 will deliver highly compelling efficacy in future infant datasets.
---
Ownership Overview
0.80% Insiders
46.92% Mutual Funds
0.09% Other Institutional Investors
35.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PCVX FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was $28.46 and its highest was $121.06 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Vaxcyte, Inc.’s market cap is $4.19B.
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is May 12, 2025 which is in 33 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on Feb 25, 2025. The company reported -$1.02 earnings per share for the quarter, beating the consensus estimate of -$1.107 by $0.087.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -1.05.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 128,761,630 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -$1.02 in its last earnings report, beating expectations of -$1.107. Following the earnings report the stock price went down -0.882%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Currently, no hedge funds are holding shares in PCVX
---
Vaxcyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$124.13 (311.03% Upside)
$124.13 (311.03% Upside)
Blogger Sentiment
Bullish
PCVX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 605.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.2%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.87%
12-Months-Change
Fundamentals
Return on Equity
-20.41%
Trailing 12-Months
Asset Growth
150.96%
Trailing 12-Months
Company Description
Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
---
PCVX Company Deck
---
PCVX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Vaxcyte's strong financial position, significant clinical and manufacturing progress, and proactive regulatory engagement. However, challenges include increased expenses, potential regulatory uncertainties, and the need to meet non-inferiority criteria in clinical studies. Vaxcyte remains optimistic about its pipeline and future growth.Read More>---
PCVX Stock 12 Month Forecast
Average Price Target
$124.13
▲(311.03% Upside)
Technical Analysis
Best Analysts Covering PCVX
1 Year
1 Year Success Rate
9/15 ratings generated profit
1 Year Average Return
+22.13%
reiterated a buy rating 10 days ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +22.13% per trade.
---